Agenda

Friday: September 16, 2022

6:30pm-8:00pm

Welcome Reception

Saturday: September 17, 2022

8:00am

Introduction & Meeting Objectives
Naval Daver & Andrew Wei

8:10am-9:30am

Session 1: Current challenges in clinical genomics
Chairs:  Bob Löwenberg & Paresh Vyas

  • CHIP and clonal hematopoiesis in relation to AML; Koichi Takahashi
  • Genomics and their clinical application for secondary AML; Paresh Vyas
  • Germline predispositions in AML; Jean Soulier
  • Fitness of leukemic stem cells; Claudia Lengerke
  • Current challenges in clinical genomics; Courtney DiNardo
    Panel Discussion

9:30am-11:10am

Session 2: What is standard of care in AML in 2022
Chairs: Mark Levis & Eunice Wang

  • Improving intensive chemo approaches in frontline AML; Eunice Wang
  • Maintenance therapy for whom?; Andrew Wei
  • Which patients should have allo transplant in 2022; Charles Craddock
  • Optimal Transplant conditioning regimen in AML; Alessandro Rambaldi

Panel Discussion

  • Optimizing therapy in secondary AML/RWE CPX; Christina Rautenburg
  • Targeted approaches for IDH-mutated AML: Venetoclax or IDHi?; Stephane DeBotton
  • Current approach for relapsed FLT3-mutated AML; Jessica Altman

Panel Discussion

11:10am-11:30am

Break

11:30am-11:50am

Keynote ALL talk:  Innovation in the treatment of T- ALL
Daniel DeAngelo

11:50am-1:00pm

Session 3 : Novel Treatment Strategies in ALL
Chairs: Dieter Hoelzer & Sabina Chiaretti

  • Ponatinib combination strategies; Nicholas Short
  • Progress in treatment of AYA ALL; Nicolas Boissel
  • Open questions in PH+ ALL; Robin Foa
  • Updates in asparaginase treatment strategies; Rob Pieters

Panel Discussion

1:00pm-2:00pm

Lunch

2:00pm-3:20pm

Session 4a: New frontiers in MRD for ALL clinical practice
Chairs: Catherine Smith & Roland Walter                                                                                                  How to improve

  • How to improve MRD detection: ddPCR, NGS: Sabina Chiaretti
  • MRD in adult Ph/BCR-ABL-negative ALL: how best to eradicate?; Nicola Gökbuget

Panel discussion

Session 4b: New frontiers in MRD for AML clinical practice

  • Single cell sequencing and clinical applicability in detection and therapy of AML; Catherine Smith
  • Transplant in AML with MRD; Farhad Ravandi
  • Novel approaches for integrating MRD into clinical trials: Andrew Wei

Panel Discussion

 

3:20pm-3:50pm

Special Session– Regulatory Endpoints in AML

  • EMA perspective; TBC
  • FDA perspective; Kelly Norsworthy

3:50pm-4:10pm

Break

4:10pm-5:00pm

Session 5: MDS/BPDCN/CMML
Chair: Naval Daver & TBC

  • Updates in diagnosis, pathogenesis and future directions for BPDCN; Naveen Pemmaraju
  • Updates in CMML diagnosis and treatment, future targets; Mrinal Patnaik
  • Novel RNA-directed therapeutics for treatment of myeloid malignancies; Omar Abdel-Wahab

Panel Discussion

 

5:00pm

End of Day 1

7:00pm

Faculty Dinner

Sunday: September 18, 2022

8:00am-9:40am

Welcome Day 2 and meeting objectives

Session 6: Novel targets, combinations and treatments in AML
Chairs: Naval Daver & Marion Subklewe

 

8:10am-8:30am

Keynote:  Challenges in the treatment of high-risk AML
Richard Stone

8:30am-9:50am

Part 1: What is the next AML blockbuster?
Chairs: Charles Craddock & Jessica Altman

  • Doublet and triplet combinations in AML; Naval Daver
  • Emerging novel Antibody-Drug Conjugates; Roland Walter
  • TP53 treatment strategies in AML; Thomas Cluzeau
  • Menin inhibitors in AML; Eytan Stein
  • Anti CD47; David Sallman

Panel discussion

9:50am-10:10am

Coffee break / e-break

10:10am-11:20am

Part 2:  What do we know about drug resistance?
Chairs: Naval Daver & Stephane de Botton                                                                                               

  • Understanding and overcoming resistance to IDHi: Paresh Vyas
  • Targeting resistance to Venetoclax based therapies: Marina Konopleva
  • Resistance to FLT3 inhibitors: Alexander Perl
  • Epigenetic therapies: Carsten Müller-Tidow

Panel Discussion

 

11:20am-12:50pm

Session 7: T-cell engagement
Chairs: Sabina Chiaretti & Elias Jabbour

Roadmap on how to treat relapsed ALL

  • Use of monoclonal antibodies in the CAR T-cell era: Nicola Gökbuget
  • Inotuzumab/blinatumomab – frontline strategies in B-ALL; Elias Jabbour

 

CAR-T in ALL
Chairs: Bijal Shah & Claire Roddie

  • Predicting response to CAR-T; Bijal Shah
  • Tisagenlecleucel in B-ALL; Sara Ghorasian
  • Auto1 outcomes in adult ALL: Claire Roddie
  • Zuma-3 and brexucabtagene autoleucel indication for Adult ALL:  Nicolas Boissel
  • Allogeneic CARs in ALL; Nitin Jain

Panel Discussion

12:50pm-1:50pm

Lunch

1:50pm-3:20pm

Session VIII: Immunotherapeutic in AML
Chairs: Marion Subklewe & Saar Gill

Keynote: Pitfalls and future strategies for immunotherapies in AML
Marion Subklewe

  • Immune checkpoint inhibitor in AML; Amer Zeidan        
  • Emerging NK cell-based therapies in AML: Naval Daver
  • Which CART cell strategy in AML has the most promise: Saar Gill
  • AML for CAR-T – CLL1; Fang Liu
  • Novel targets for CAR-T in AML; Michael Hudecek

Panel Discussion

3:20pm

Closing Comments
Marion Subklewe

Meeting End

© 2017 - 2022 World Health Communications Ltd